BNP Paribas Financial Markets Sells 57,502 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

BNP Paribas Financial Markets reduced its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 60.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 36,964 shares of the company's stock after selling 57,502 shares during the period. BNP Paribas Financial Markets owned approximately 0.08% of Amphastar Pharmaceuticals worth $1,372,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in AMPH. Pacer Advisors Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 51,977.4% during the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock worth $50,139,000 after acquiring an additional 1,347,775 shares during the last quarter. Boston Trust Walden Corp lifted its stake in Amphastar Pharmaceuticals by 81.4% in the fourth quarter. Boston Trust Walden Corp now owns 978,920 shares of the company's stock worth $36,347,000 after purchasing an additional 439,281 shares during the last quarter. Boston Partners bought a new stake in Amphastar Pharmaceuticals in the fourth quarter worth $15,778,000. Wealthfront Advisers LLC bought a new stake in Amphastar Pharmaceuticals in the fourth quarter worth $9,268,000. Finally, Dimensional Fund Advisors LP lifted its stake in Amphastar Pharmaceuticals by 9.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,198,590 shares of the company's stock worth $44,503,000 after purchasing an additional 105,288 shares during the last quarter. 65.09% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Wells Fargo & Company lowered their price target on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research note on Thursday, May 8th. Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Piper Sandler lowered their price target on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research note on Friday, March 21st. Finally, JPMorgan Chase & Co. reissued a "neutral" rating and issued a $30.00 price target (down from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, Amphastar Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $32.33.

Amphastar Pharmaceuticals Price Performance

AMPH stock opened at $24.79 on Tuesday. The firm's 50-day moving average price is $25.40 and its two-hundred day moving average price is $33.54. Amphastar Pharmaceuticals, Inc. has a 12-month low of $22.64 and a 12-month high of $53.96. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of 8.26, a PEG ratio of 2.19 and a beta of 0.78. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82.

Insider Activity at Amphastar Pharmaceuticals

In related news, CFO William J. Peters sold 4,231 shares of the business's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the transaction, the chief financial officer now owns 97,363 shares in the company, valued at $2,681,377.02. The trade was a 4.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 5,231 shares of company stock worth $142,752 over the last 90 days. 27.50% of the stock is owned by company insiders.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.